INS and metabolic dysfunction-associated steatotic liver disease: In conclusion, rosuvastatin improves glucose intolerance, insulin sensitivity and NAFLD in a dose-dependent manner and changes the fat distribution from visceral to subcutaneous fat depot in a mouse model of diet-induced obesity.